is no stranger to null results, according to Spectrum's profile of the psychiatrist last month. Over the past two years, trial results from Veenstra-VanderWeele and his colleagues have shown that intranasal oxytocin and the vasopressin blocker balovaptan are each no more effective than placebo at improving social or communication challenges in autistic children.Results such as these -null or otherwise -come from carefully constructed trials founded on solid preclinical evidence, Veenstra-VanderWeele told Spectrum.